Foghorn Therapeutics Inc.
NASDAQ:FHTX

Watchlist Manager
Foghorn Therapeutics Inc. Logo
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Watchlist
Price: 5.78 USD 10.31% Market Closed
Market Cap: 326.9m USD

Wall Street
Price Targets

FHTX Price Targets Summary
Foghorn Therapeutics Inc.

Wall Street analysts forecast FHTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FHTX is 11.37 USD with a low forecast of 9.09 USD and a high forecast of 14.7 USD.

Lowest
Price Target
9.09 USD
57% Upside
Average
Price Target
11.37 USD
97% Upside
Highest
Price Target
14.7 USD
154% Upside
Foghorn Therapeutics Inc. Competitors:
Price Targets
LVTX
LAVA Therapeutics NV
20% Downside
ORKA
Oruka Therapeutics Inc
57% Upside
688278
Xiamen Amoytop Biotech Co Ltd
19% Upside
RNA
Avidity Biosciences Inc
3% Upside
MRSN
Mersana Therapeutics Inc
17% Upside
KURA
Kura Oncology Inc
199% Upside
ARX
Aroa Biosurgery Ltd
23% Upside
688363
Bloomage Biotechnology Corp Ltd
10% Upside

Revenue
Forecast

Revenue Estimate
Foghorn Therapeutics Inc.

The compound annual growth rate of Foghorn Therapeutics Inc.'s revenue for the next 4 years is 27%.

N/A
Past Growth
27%
Estimated Growth
Estimates Accuracy
-28%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Foghorn Therapeutics Inc.

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat

Net Income
Forecast

Net Income Estimate
Foghorn Therapeutics Inc.

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-26%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is FHTX's stock price target?
Price Target
11.37 USD

According to Wall Street analysts, the average 1-year price target for FHTX is 11.37 USD with a low forecast of 9.09 USD and a high forecast of 14.7 USD.

What is Foghorn Therapeutics Inc.'s Revenue forecast?
Projected CAGR
27%

The compound annual growth rate of Foghorn Therapeutics Inc.'s revenue for the next 4 years is 27%.

Back to Top